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Reply
We thank Drs. Marenzi and Aspromonte for their thoughtful
comments, which seemed to share the same consideration we have
discussed at length that both cardiac and renal compromise may be
too far gone to benefit from hemodynamic improvements achieved
via slow continuous ultrafiltration (SCUF) in patients refractory to
standard medical therapy (1). Our nephrology consultants custom-
arily prescribe renal replacement therapy upfront if there were any
clinical suspicions of established or evolving acute kidney injury. In
addition, only those who had received at least 48 h of SCUF
without the need for renal replacement therapy conversion were
included in the analysis. Therefore, the likelihood of a progressive
acute kidney injury scenario is relatively low in our study cohort.
We agree with Drs. Marenzi and Aspromonte that excessive fluid
removal at a rate inadequately balancing plasma refill rate may pose
detrimental consequences. Nevertheless, our SCUF protocol was
collaboratively conducted by nephrologists and cardiologists with
direct central hemodynamic measurements as well as careful
clinical monitoring in a dedicated heart failure intensive care unit.
Therefore, we have reliable assurance that the large majority of
subjects were able to maintain adequate intravascular filling pres-
sures (Fig. 1 in the original paper). This may also be reflected by
the lack of significant changes in hemoglobin or albumin over time
(1). The divergence between total protein measurements and
hematocrit was likely due to the relatively large variabilities in a
relatively small sample size (of note, the mean admission totalprotein was 6.3  1.1 g/dl) rather than overzealous removal of salt
and volume.
The latest clinical guidelines in the care of patients with heart
failure stated that “ultrafiltration is reasonable for patients with
refractory congestion not responding to medical therapy” (2).
While there are theoretical benefits and successful attributes of
SCUF use in selective patients, recent prospective clinical trial data
have provided the same cautionary note that SCUF may not be
advantageous over intensive pharmacologic therapy in the setting
of worsening renal function (3). Indeed, the invasiveness and costs
associated with SCUF can only be justified if there is a consistent
and reproducible benefit over standard medical therapies in a
well-defined population. Therefore, it is our opinion that any
further alternative explanations of discrepancies between perceived
advantages and observed lack of benefits can only be clarified with
refinement in techniques for this challenging population and
further careful clinical investigations.
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